文献速递系统性红斑狼疮

血清syndecan-1、透明质酸和血栓调节蛋白在狼疮肾炎中的水平

Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

研究检测了经活检证实的III/IV±V型狼疮肾炎(LN)患者血清syndecan-1、透明质酸(HA)和血栓调节蛋白水平及其与临床病理的关联。结果显示活动期LN中三者均显著升高,与蛋白尿、eGFR、抗dsDNA抗体等指标相关,且syndecan-1和血栓调节蛋白在临床肾脏复发前3.6个月即升高,对活动性LN具有良好鉴别能力。

要点

  • 活动期LN患者血清syndecan-1、HA和血栓调节蛋白水平显著高于缓解期(P<0.01)。
  • syndecan-1和血栓调节蛋白在肾脏临床复发前3.6个月升高,HA在肾炎复发时升高。
  • syndecan-1和血栓调节蛋白可区分活动性LN与健康人、缓解期LN、活动性非肾性狼疮及非狼疮慢性肾病。

核心结论

  • 血清syndecan-1、血栓调节蛋白和HA水平在LN临床管理中具有潜在应用价值,并可能参与LN发病机制。

研究设计与样本

  • 研究纳入经活检证实的III/IV±V型LN患者,以非肾性SLE、非狼疮慢性肾病患者及健康者为对照,采用ELISA检测血清syndecan-1、HA和血栓调节蛋白水平。

主要发现

  • 活动期LN中syndecan-1、HA和血栓调节蛋白水平显著高于缓解期(P<0.01),且与蛋白尿水平、估算肾小球滤过率、抗dsDNA抗体、补体3和血清肌酐相关。
  • 纵向研究显示syndecan-1和血栓调节蛋白在临床肾脏复发前3.6个月升高,HA在肾炎复发时升高,三者水平随治疗反应平行下降。
  • ROC曲线分析显示syndecan-1区分活动性LN与健康人、缓解期LN、活动性非肾性狼疮及非狼疮慢性肾病的AUC分别为0.98、0.91、0.82和0.95。
  • 血栓调节蛋白区分上述四组的AUC分别为1.00、0.84、0.97和0.79。
  • HA区分活动性LN与健康人、缓解期LN及非狼疮慢性肾病的AUC分别为0.82、0.71和0.90,但不能区分肾性与非肾性狼疮。

关键数值与推荐

  • syndecan-1区分活动性LN与健康人、缓解期LN、活动性非肾性狼疮及非狼疮慢性肾病的AUC分别为0.98、0.91、0.82和0.95。
  • 血栓调节蛋白区分上述四组的AUC分别为1.00、0.84、0.97和0.79。
  • HA区分活动性LN与健康人、缓解期LN及非狼疮慢性肾病的AUC分别为0.82、0.71和0.90。

临床怎么用

  • 血清syndecan-1和血栓调节蛋白可能作为活动性LN的鉴别标志物,并在临床肾脏复发前3.6个月提示复发风险。
  • HA水平可用于区分活动性LN与非狼疮慢性肾病,但不能区分肾性与非肾性狼疮。

局限性

  • 原文未报告样本量、具体阈值、95%CI及多变量分析结果。
  • 研究为单中心设计,结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We investigated circulating syndecan-1, HA and thrombomodulin levels in patients with biopsy-proven Class III/IV ± V LN and their clinico-pathological associations. Patients with non-renal SLE or non-lupus chronic kidney disease, and healthy subjects served as controls. METHODS: Serum syndecan-1, HA and thrombomodulin levels were determined by ELISAs. RESULTS: Syndecan-1, HA and thrombomodulin levels were significantly higher during active LN compared with remission (P < 0.01, for all), and correlated with the level of proteinuria, estimated glomerular filtration rate, anti-dsDNA antibodies, complement 3 and serum creatinine. Longitudinal studies showed that syndecan-1 and thrombomodulin levels increased prior to clinical renal flare by 3.6 months, while HA level increased at the time of nephritic flare, and the levels decreased in parallel with treatment response. Receiver operating characteristic curve analysis showed that syndecan-1 and thrombomodulin levels distinguished patients with active LN from healthy subjects, LN patients in remission, patients with active non-renal lupus and patients with non-lupus chronic kidney disease (receiver operating characteristic area under curve of 0.98, 0.91, 0.82 and 0.95, respectively, for syndecan-1; and area under curve of 1.00, 0.84, 0.97 and 0.79, respectively, for thrombomodulin). HA level distinguished active LN from healthy subjects, LN patients in remission and non-lupus chronic kidney disease (receiver operating characteristic area under curve of 0.82, 0.71 and 0.90, respectively) but did not distinguish between renal vs non-renal lupus. Syndecan-1 and thrombomodulin levels correlated with the severity of interstitial inflammation, while HA level correlated with chronicity grading in kidney biopsies of active LN. CONCLUSION: Our findings suggest potential utility of serum syndecan-1, thrombomodulin and HA levels in clinical management, and their potential contribution to LN pathogenesis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yu KYC, Yung S, Chau MKM, et al. Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis. Rheumatology (Oxford). 2021. PMID: 32793966. doi:10.1093/rheumatology/keaa370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。